Health
Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test – News-Medical.net
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expan…
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.
Avacta, in partnership with Cytiva, is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the S…
-
Business23 hours ago5 things to watch on the ASX 200 on Monday 1 September 2025
-
Noosa News23 hours agoStar Brisbane cricketer finds home in suburb with shocking popularity rise
-
Noosa News10 hours agoMassive wind farm project in Queensland axed amid community backlash
-
Business14 hours agoIAG shares are racing higher today. Here’s why